Regenxbio Inc Cash Flow Conversion Efficiency
Regenxbio Inc cash flow conversion efficiency. Based on the latest financial reports, Regenxbio Inc (RGNX) has a cash flow conversion efficiency ratio of -0.867x as of June 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-62.24 Million) by net assets ($71.77 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Cash Flow Conversion Efficiency of Regenxbio Inc (2013–2025)
Cash flow conversion efficiency of Regenxbio Inc from 2013 to 2025. This chart illustrates how Regenxbio Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. View RGNX share price today for real-time trading data and today's change.
Regenxbio Inc Cash Flow Conversion Ratio Explained
Regenxbio Inc cash flow conversion ratio divides operating cash flow by net assets, so a higher ratio means more cash generated from each unit of shareholder equity.
Regenxbio Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Regenxbio Inc ranked by their cash flow conversion efficiency. Also see RGNX company net worth for the company's overall valuation and market capitalisation.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
BlackRock MIT II
NYSE:BLE
|
-0.063x |
|
Gansu Yatai Industrial Development Co Ltd
SHE:000691
|
-0.880x |
|
Chipsea Technologies Shenzhen Corp Ltd
SHG:688595
|
-0.046x |
|
Shanghai Material Trading Co Ltd A
SHG:600822
|
0.023x |
|
Crescent Biopharma, Inc.
NASDAQ:CBIO
|
-0.119x |
|
Oncology Institute Inc
NASDAQ:TOI
|
0.136x |
|
Solomon Technology Corp
TW:2359
|
0.010x |
|
Lem Holding SA
SW:LEHN
|
0.074x |
Annual Cash Flow Conversion Efficiency for Regenxbio Inc (2013–2025)
The table below shows the annual cash flow conversion efficiency of Regenxbio Inc from 2013 to 2025. Review Regenxbio Inc free cash flow efficiency to assess how much free cash flow the company generates relative to operating cash flow.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $102.73 Million | $-123.96 Million | -1.207x | -80.97% |
| 2024-12-31 | $259.65 Million | $-173.12 Million | -0.667x | +4.83% |
| 2023-12-31 | $311.74 Million | $-218.41 Million | -0.701x | -74.30% |
| 2022-12-31 | $516.20 Million | $-207.49 Million | -0.402x | -240.36% |
| 2021-12-31 | $764.30 Million | $218.88 Million | 0.286x | +300.10% |
| 2020-12-31 | $377.75 Million | $-54.06 Million | -0.143x | +40.18% |
| 2019-12-31 | $450.20 Million | $-107.70 Million | -0.239x | -216.33% |
| 2018-12-31 | $508.85 Million | $104.65 Million | 0.206x | +164.91% |
| 2017-12-31 | $183.03 Million | $-57.99 Million | -0.317x | -5.54% |
| 2016-12-31 | $161.74 Million | $-48.56 Million | -0.300x | -189.10% |
| 2015-12-31 | $216.81 Million | $-22.52 Million | -0.104x | -124.67% |
| 2014-12-31 | $-5.70 Million | $-2.40 Million | 0.421x | -70.04% |
| 2013-12-31 | $-2.14 Million | $-3.01 Million | 1.406x | -- |
About Regenxbio Inc
REGENXBIO Inc., a clinical-stage biotechnology company, provides gene therapies that deliver functional genes to cells with genetic defects in the United States. Its gene therapy product candidates are based on NAV Technology Platform, a proprietary adeno-associated virus gene delivery platform. The company's products in pipeline includes ABBV-RGX-314 for the treatment of wet age-related macular … Read more